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Human papillomavirus (HPV) with and without clinical lesions is the most common viral infection of the reproductive tract in men and women, and an estimated 630 million people worldwide are believed to be infected with HPV (Centers for Disease Control and Prevention [CDC], 2016). Most sexually active women and men will be infected at some point in their lives and some may be repeatedly infected (World Health Organization [WHO], 2016). Genital HPV infections are the most common STD, but are largely transient, asymptomatic, and of no consequence. Globally, 50% to 80% of sexually active women are infected by HPV at least once in their lives (Crum, Abbott, & Quade, 2003). Usually women contract HPV between their late teenage years and early 30s, with the peak of infection shortly after becoming sexually active.
On a global scale, the crude incidence rates have shown that cervical cancer is the third most common cancer in women worldwide after breast and colorectal cancer, excluding non-melanocytic skin cancers. Less developed regions have a population of 2,174 million women aged 15 years and older who are at risk of developing cervical cancer. Current estimates indicate that 527, 624 women were diagnosed with cervical cancer, and there were 265,672 deaths in 2012 (Institut Català d'Oncologia [ICO], 2015a).
In developed countries, programs are in place that enable women to get screened, making most pre-cancerous lesions identifiable at stages when they can easily be treated. Early diagnosis prevents up to 80% of cervical cancers in these countries. In developing countries, limited access to effective screening means that the disease is often not identified until it is further advanced and symptoms develop. In addition, prospects for treatment of such late-stage disease may be poor, resulting in a higher rate of death from cervical cancer in these countries. About 3.8% of Chinese women are estimated to harbor cervical HPV-16/18 infection at a given time and cervical cancer ranks as the eighth most common cancer among women in China and the second most frequent cancer among women between 15 and 44 years old. China has a population of 557.32 million aged 15 yeas and older who are at risk of developing cervical cancer. Current estimates indicate that every year 61,691 women are diagnosed with cervical cancer and 29,526 die from the disease (ICO, 2015b). In China, wide disparities in cervical cancer incidence and mortality exist, and are mainly attributable to the large population, diverse ethnic groups and the unequal economic development in different areas across the country (Shi et al., 2008). Differences in lifestyles, such as sexual behaviors, educational levels, and numbers of pregnancies are established risk factors for HPV exposure or persistent infection (Li et al., 2011).
This essay provides characteristics of HPV-related cervical cancer, cervical cancer screening practices and HPV vaccine introduction in China. The essay suggests guidelines for health policy implementation of primary and secondary cervical cancer prevention strategies in China. 

2.0 	Current Burden of HPV-Related Cervical Cancer in China
2.1	HPV Type-Distribution in Cervical Cancer in China
Human Papillomaviruses (HPV) are simple, non-enveloped, double-stranded deoxy-ribonucleic acid (DNA) viruses belonging to the Papillomaviridae. More than 200 genotypes have been identified, causing benign (low-risk, LR-HPV) or malignant (high-risk, HR-HPV) cutaneous or mucosal lesions (Borruto & De Ridder, 2012). LR-HPV types (known by the number 6, 11, 40, 42, 43, 44, 53, 54, 61, 72, 73 and 81) cause genital warts, abnormal cervical cytology, recurrent respiratory papillomatosis, or, most commonly, infections that go unnoticed and eventually clear up. High-risk types (known by the numbers 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68) cause most anogenital cancers (anus, vulva, vagina and penis), while types 16 and 18 are the most common cancer-causing types worldwide and are associated with about 70% of all cases of cervical cancer, including 41% and 67% of high-grade cervical lesions and 16-32% of low-grade cervical lesions (Clifford et al., 2006; Smith et al., 2007). After HPV 16/18, the six most common HPV types are the same in all world regions, namely 31, 33, 35, 45, 52 and 58; these account for an additional 20% of cervical cancers worldwide (Clifford et al., 2006). Although most HPV infections clear up on their own and most pre-cancerous lesions resolve spontaneously, there is a risk for all women that HPV infection may become chronic and pre-cancerous lesions may progress (CIN-1, CIN-2, CIN-3/CIS) to invasive cervical cancer (ICC). It takes 15 to 20 years for cervical cancer to develop in women with normal immune systems. In contrast, it can take only five to 10 years in women with weakened immune systems, such as those with untreated HIV infection (WHO, 2016). 
A multicenter study was conducted in China to determine the distribution of HPV types ICC and CIN 2/3 in women from different regions within China. A total of 1,233 cases (630 squamous cell carcinoma [SCC], 433 CIN3, and 136 CIN2) were histologically confirmed with valid HPV DNA testing results across seven geographical regions (Northeast, North, Northwest, Central, Southwest, South and East China). Overall, HPV 16 was the most common type (76.7%), followed by HPV 18 (7.8%), HPV 31 (3.2%), HPV 52 (2.2%), and HPV 59 (2.1%). In SCC cases, no low-risk HPV type was found alone, but always as a co-infection with another oncogenic HPV type. HPV 16 prevalence in squamous cell carcinoma was similar across the seven geographical regions surveyed, ranging from 70.7% in the East to 81% in Northeast. HPV 18 prevalence ranged from 6.4 to 10.8% across regions, with the exception of the Central region (3.6%) where HPV 31 was the second most common type after HPV 16. The third most common type was HPV 31 in the North and East regions, HPV 59 in Northeast and Northwest regions, HPV 52 in Southwest and South regions, and HPV 58 in Central region. Among 569 CIN2/3 biopsy specimens, overall HPV DNA prevalence did not significantly differ by geographical region, ranging from 97.3% in Northeast to 100% in Central, Southwest, and South China (Chen et al., 2009). Generally, Chinese women suffer from a high prevalence of CIN2/3 and the predominant HPV genotypes are HPV 16, 18 and 52 in SCC, which slightly differ by geographic regions.  

2.2	HPV Prevalance in Rural and Urban Areas in China
HPV prevalence showed a similar pattern among different age groups but the rate varied in urban and rural Chinese women. In rural areas, the HPV prevalence was higher than that in urban women. A pooled analysis of 17 population-based studies noted a crude HR-HPV prevalence of 18.0% in rural women and 15.2% in urban women. However, the most commonly used method for detection of HPV DNA was different between rural (HC2) and urban (GP5+/6+ mediated PCR) areas (Li, Huang, Schmidt, & Qiao, 2013). Besides, potential bias may be present because most rural studies were located in high risk areas in China. Therefore, the higher rates of HPV prevalence in rural area should be interpreted cautiously. 
2.3	HPV Prevalence in Different Ethinic Groups
Covering approximately 9.6 million square kilometers, China is the world’s second-largest country by land area, and it has the largest population in the world, containing 56 distinct ethnic groups that populate some specific provinces. As geographic location and ethnicity are potential factors related to HPV infection and cervical cancer development, it is essential to investigate the HPV prevalence, genotype distributions, and contributory risk factors in certain areas in China. Recently, a study in Yunnan found that the prevalence of overall HR-HPV, and single genotype HPV infections was significantly higher among Tibetan women than among Naxi and Han women (Baloch et al., 2016). Other studies also demonstrated 7.3% HR-HPV positive results in Uyghur women (Husaiyin et al., 2015), 7.6% in Maonan women (Guizhou province) (Wei et al., 2010), and 9.1% in Tibetan women (Jin et al., 2009). Unique geographic location, highly complex topography, diversity of ethnic minorities, genetic variation and distinctiveness of social characters are likely to contribute to the observed differences.
2.4	HPV Prevalence among Different Age Groups
When stratified by age, a dual-peak pattern pertained to both rural and urban women. The first peak of crude HPV prevalence was 16.2% and 18.7% among women aged 15-24 in rural and urban areas respectively. The second peak was at age 35-39 years (18.6%) among rural women and among women older than 40 years of age (16.0%) in urban areas.   This pattern differs from that observed in women from Western countries, among whom HPV prevalence peaked in their mid-twenties, then steadily declined as age increased (ICO, 2015b).
A multicenter survey among women 15 to 59 years old further confirmed the appearance of the first peak by comparing the age of women’s sexual debut with their sexual behavior. There is a trend that women begin sexual intercourse at younger ages than in the past, which puts young women at risk for HPV earlier in life and increases the pool of at-risk sexually active young people.  At the time of the interview, among the 15-19 years-old age group more urban women (10.8%) than rural women (4.5%) had experienced sexual activity with a partner, while among women aged in the 20-24 years, the proportions increased to 62.2% and 44.4% of rural and urban women, respectively.
 Furthermore, the trends in sexual behavior exhibited by young Chinese women include starting menarche at younger age, having more sexual partners, having sexual partners who have multiple partners, and not cleaning the genitals after sexual intercourse (Zhao et al., 2012). The increased saliency of sexual risk factors in China, a traditionally conservative culture, may be a result of the behavioral changes stemming from the rapid industrialization and urbanization the country has experienced during the past two decades (Zhao et al., 2010). 
Reasons for the second peak could be a cohort effect since most women aged 49-65 got married at an early age and had a large number of births before the implementation of one-child policy. However, long-term follow-up studies with birth cohort analysis are needed to further clarify this effect. The unexpected higher incidence in older women may be caused by new HPV infections acquired by changes in sexual behaviors by either the women or their partners, or reactivation of latent HPV infection due to weakened immune response after menopause. Another explanation was strongly supported by an obvious trend of decreasing ability to defeat recent HPV infections or long persistence of HPV in older women from earlier exposures (Kang et al., 2014). 
Type-specific HPV prevalence also showed an age trend in a population based multicenter study.  HPV type 16 was more commonly found among younger cases (<35 years), in contrast with HPV types HPV 52, 58, and 39 which were more frequent in older age cases (≥50 years). The higher prevalence of HPV 16 in younger SCC cases might reflect the higher probability that women with HPV 16 progress more quickly to more serious high-grade pre-cancer or invasive cervical cancer than other oncogenic HPV types, as previously described. Alternatively, it might reflect a change in patterns of exposure to HPV infection among young Chinese women compared to older generations (Chen et al. 2009). 
3.0 	Current Prevention Status
Currently, two prophylactic HPV vaccines are commercially available, Gardasil (Merck & Co., USA) and Cervarix (GlaxoSmith- Kline, Belgium). Both vaccines target HPV-16 and -18, which cause 70.1% of invasive cervical cancers worldwide (Clifford et al., 2003; Muñoz et al., 2004; Smith et al., 2007). The Gardasil vaccine additionally targets HPV-6 and -11, responsible for about 83% of genital warts (Wang & Qiao 2008). These HPV vaccines are heralded as promising methods to decrease HPV infection and cervical cancer incidence and have been widely utilized in many developed countries. Since the original global multicenter clinical trials for the WHO recommended HPV vaccines did not include mainland China, redoing the clinical trials was unavoidable. Since 2008, both vaccine companies have conducted clinical trials in China and prepared to apply for approval from the State Food and Drug Administration. Additionally, a Chinese domestic HPV prophylactic vaccine targeting HPV 16 and 18 started its Phase III clinical trials in 2012, and is expected to produce results in 2016 (Wang & Qiao 2014).












4.0 	Knowledge and Attitudes toward HPV and Cervical Cancer in China
Previous studies on prevalence of HR-HPV infection and CIN2/3 suggest that China could face a significantly increased cervical cancer burden if comprehensive vaccination and screening programs are not implemented. With demands for popularizing cervical cancer screenings, while lacking vaccination, it is essential to explore the knowledge of HPV-related cervical cancer, attitudes and acceptability of HVP vaccination and screening of both rural and urban women among Chinese women. 
All the studies conducted in the past few years revealed that HPV awareness is low throughout the country and is inadequate even among HPV-aware women. A cross-sectional study of 8,188 women aged 15-59 year was created across China. Of these women, only 15.0% reported ever having heard of HPV, this knowledge differs by rural (9.3%) and metropolitan areas (21.6%) (Li et al., 2009). In Zhejiang, an eastern coastal province of China, 39.1% of women in urban areas and 27.1% in rural areas had heard of HPV (Feng, et al., 2011). In Yangchen, a typical low-income county located in central China, very few (5.9%) women reported having ever heard of HPV (Li et al., 2015). Also, the knowledge of HPV does not guarantee accurate knowledge about its link to cervical cancer and genital warts. Only 48.2% of women who had ever heard of HPV knew that HPV is related to cervical cancer; very few (8.1%) knew that it is associated with genital warts (Li et al., 2009). Almost all had a number of misconceptions about the correlation between HPV and cervical cancer, especially among rural women. They did not understand that being sexually active already constituted a risk. Furthermore, the majority of the participants identified that HPV infections were symptomatic diseases, could be cured and could only occur in women. 
In all the studies, a majority indicated that they were willing to participate in HPV vaccination or cervical cancer screenings. HPV awareness and knowledge were directly related to acceptance of HPV vaccination and screenings. Doubts about the source of the HPV vaccine and its safety were the major reasons for women’s unwillingness to get themselves and their daughters vaccinated followed by the opinion that it was unnecessary. Fear of already having been infected was the major reason for them to be vaccinated, which reflects the lack of knowledge about prophylactic vaccines (Li et al., 2009). The most commonly reported barriers for women to undergo cervical cancer screenings were the anticipated feeling of anxiety once the disease was diagnosed and a lack of symptoms or discomfort. The anxiety is due to inadequate information about the intent of cervical cancer screenings. However, the latter indicates that focusing on health crises rather than disease prevention is an element of Chinese culture (Jia et al., 2013). 
Nearly half of the participants also perceived an adverse impact on their relationships with partner, family or friends if they were HPV infected, especially in rural areas. Some even mentioned that the impact was considered serious enough to end their intimate relationship (Kwan et al., 2009). In addition, the average age they thought would be appropriate to get vaccinated was 20.5 (SD:3.7) years old (Hu et al., 2011), and some participants did not agree with vaccinating virgins (Kwan et al., 2009). In terms of HPV vaccine cost, though urban women were willing to pay more, very few women were willing to pay more than 50-100 RMB (US$ 8-15). More than half of women thought HPV vaccination should be fully government-subsidized or at least partly covered (Li et al., 2009; Hu et al., 2011).
5.0 	Overall Challenges of Promoting HPV Vaccination and Cervical Cancer Screening
Although great achievements have been made on cervical cancer prevention and control by promoting early detection and treatment, challenges still exist and more efforts need to be made. The high prevalence of HR-HPV infection and CIN2+ in China suggests heavy cervical cancer burden in China. Although prevalence of HPV in rural areas is consistently higher than in urban areas, the age related dual-peak HPV prevalence pattern is similar in both areas. In addition, the mortality caused by cervical cancer is unbalanced between rural and urban Chinese women; thus, more attention should be paid to rural women living in central and western China, where health care resources as well as access to care are limited. Other factors such as different marriage practices (polygamy, monogamy, etc.), traditional health practices, and distinctive geographic location, highlight the significant variation in the prevalence and genotype distribution of HPV among local people in regions with various ethnic groups. There is also age related HR-HPV prevalence among Chinese women because of the variations in sexual and reproductive behavior in the past 30 years. One alarming trend observed was that the risk of cervical cancer is becoming more severe in younger women. The bimodal distribution of HPV prevalence by age will have significant programmatic implications for cervical cancer screening policies in China.
Currently, cervical cancer screenings covered only 7% of women who are 35-59 years old, and those programs mainly focused on rural women. With a total of 822 million women aged 21-65 (estimated on the basis of the Chinese Population Census of 2010), there are huge demands for the coverage of cervical cancer screening in both rural and urban area. Also, previous screening programs encountered substantial challenges in shortages of gynecologists and cytologists in an already overburdened health-care system. Technically, changing the current subjective screening method to objective methods is necessary. Furthermore, rapid screening coverage expansion requires exploration of solid sample carriers as an alternative to the current liquid-based sample carriers, which have limitations of large sample volume, risk of leakage and restriction of storage and transportation, especially in remote rural areas. 
Although over 140 countries and areas have approved the HPV vaccine, it still remains absent on the Chinese market. HPV and cervical cancer awareness is quite low in Chinese women compared to women in developed countries. Lacking specific knowledge of HPV and cervical cancer could lead to making an uninformed decision about HPV vaccination and might result in cervical cancer screening being discontinued once a vaccination is produced. Besides, from the report, the acceptance age of women to be vaccinated is over 18 years old, which might be too late to serve certain women before their sexual debut since around 18% of both urban and rural among 15-19 years old were no longer in school, and 29.7% of that group were sexually active (Zhao et al., 2012). 
Barriers for getting cervical cancer screening include lack of seeking disease prevention advice and conservative social norms. Most women have trust in doctors or nurses and hospital lectures, which indicated the potential for specific trainings to health professionals. Concern about financial costs and affordability are highlighted by the huge gap between the cost and acceptable price of HPV vaccination.

6.0 	Strategies to Promote HPV Vaccination and Cervical Cancer Screening in China
To date, the core cervical cancer prevention and control strategy depends on early detection and treatment by the universal coverage screening program. Time is still needed to introduce prophylactic vaccines. Fortunately, a large number of epidemiology, etiology, population-based studies and the work of procuring the vaccine are well on their way. Here we summarize the strategies to promote HPV vaccination and cervical cancer screening from public health point of view.
In order to bridge the gap of health disparities and realize the goals of reducing HPV-related cervical cancer nationwide, it is essential to undertake region driven approaches for cervical cancer prevention and control. Based on current screening results, women older than 60 should also be screened as they might harbor a substantial proportion of precancerous cervical lesions that accumulated over time and may still be the target of life-saving treatments. At present, most HPV tests are liquid-based sample carriers that have limited the volume of samples carried or stored, as well as increase the risk of leakage during transportation. Thus, expansion in the number of gynecologists and cytologists and successful development of a solid sample carrier are expected to play an active role in increasing sample collection and transportation. Efforts to expand the coverage and standardize the screening method on a national scale are required. 
With the potential for cervical cancer epidemics and the task of control the HPV infection, in the long term the introduction of vaccines is urgently needed in China to reduce the disease burden of HPV infections. The existing vaccines against HR-HPV are effective for only genotypes 16 and 18; however, HPV-58, 52, 33 and 31 are also highly prevalent among various Chinese populations. Therefore, a modified HPV vaccine and the development of new-generation vaccines for additional oncogenic HPV types are vital for the prevention of cervical cancer in Chinese women. Further, an immunization schedule for nationwide vaccination of adolescent girls based on WHO recommendations and the sociocultural context in China should be established. HPV vaccination between the age of 13 and 15 years should be recommended in China due to the downward trend of sexual debut and age at menarche. What is more, it could cover 15-19-year-olds who are no longer in school but sexually active. Besides, it would also ensure access for rural women to HPV vaccination before they leave school and have less consistent access to healthcare after leaving school. Vaccinating well before the median age of sexual debut will ensure that the majority of adolescents are vaccinated before exposure to HPV to most effectively decrease their risk of developing cervical cancer. 
Based on lessons from both developed and developing countries, secondary prevention alone cannot fully reduce the incidence and the disease burden, and neither does the vaccination program. As a preventive tool, both these vaccines target girls and women not yet exposed to the risk of infection with limited intervention of HPV types. Projects which combine HPV vaccination with a cervical cancer screening should be explored in certain areas of China. Studies proved that ongoing vaccination combined with two rounds of screening would provide a balance between a requirement to implement cost-effective strategies, whilst yielding short and long term cervical cancer reductions in the population (Canfell et al., 2011). 
In order to ensure a high level of acceptance of vaccination to prevent cervical cancer, especially in the rural areas, education and HPV awareness campaigns are urgently needed. Social, cultural, and religious contexts will have to be considered. While maximizing the prophylactic potential of the vaccine requires administration before sexual debut, HPV vaccination education in China emphasizing the prophylactic nature of the vaccine must be provided to female Chinese teenagers. The need for continued cervical cancer screening should be addressed for sexually experienced women with or without HPV vaccination. It is also necessary to highlight that the recently available HPV vaccines can protect against only specific HPV types. Therefore, women who have had the vaccine still have risk of HPV infection. Furthermore, education should especially focus on those living in rural areas, and those who are older than 40 years old with low educational level and who have never had cervical screening. For both rural and urban women, recommendations from doctors or nurses to get vaccinated and educational lectures carried out in hospitals can play an important role in helping women make prevention decisions. Focusing on education of medical staff regarding HPV vaccines and cervical screening, especially community health workers and those in local clinics is a critical initial step of such a campaign. It is also an efficient way to deliver vaccines against HPV by health professionals to women and their daughters. 
Reports that are science-based and suitable for the public should be encouraged to spread related knowledge abroad by using different media. For example, it is more efficient to advertise between prime time in rural areas than post a microblog on the internet because television is the most common media and it can reach illiterate people. When designing and implementing education campaigns, relevant government departments have to use different dissemination strategies depending on different regions, the age and education levels of audience as well as the cost. Because the vaccination is targeted initially at girls before they become sexually active, it is also advisable to include the knowledge of HPV and its vaccine as part of school education.  The focus of health promotion messages should also be men, who have a strong influence over the vaccination behaviors of their wives and daughters. Education should also focus on promoting other HPV-related risks, for example, safer sexual behavior such as condom use and abstinence or the personal hygiene behaviors. In areas where illiteracy is high, awareness can be increased through culturally sensitive programs. Another relevant point is that the full benefits of vaccine will be realized after a temporal lag, so it is important to monitor and evaluate the impact of the vaccine. Cooperation between the community leaders and local health providers is necessary to help educate and provide valuable material and social support to the community. Thus, education for health officials and policy-makers is also crucial to ensure the priority is given to the vaccination. 
There are a lot of concerns highlighting the need for lowering vaccine prices, developing cost-efficient mechanisms for delivery vaccination and expanding the coverage of cervical screening to high-risk and high-burden populations, as well as identifying sources of financing. The introductory price will need to be drastically lowered through government price negotiations with vaccine manufactures. The GAVI Alliance has subsidized the vaccine in low-income countries to increase financial feasibility for the introduction. As a developing country, China could apply for support from such organizations to lower the vaccine prices. Currently, Gardasil and Cervarix are the only HPV vaccines on the market, but Xiamen Innovax Biotech and Beijing Wantai Bio-pharm have completed enrolment in phase III trial in HPV infections in China since 2014. 
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